Seon Hee Shin

Seon Hee Shin

Auto-generated profile, based on publicly available information

Seon Hee Shin

Department of Pediatrics, Hallym University Dongtan Sacred Heart Hospital, Hallym University College of Medicine, Hwaseong, Korea

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 April 2023 in Annals of Laboratory Medicine
Verified
Journal Article
Open access
PDF file
EJEun Ju Jung
Eun Ju Jung
SLSu Kyung Lee
Su Kyung Lee
SSSeon Hee SHIN
Seon Hee SHIN
JKJin Soo Kim
Jin Soo Kim
HWHeungjeong Woo
Heungjeong Woo
HKHyun Soo Kim
Hyun Soo Kim
Eun Ju Jung, M.D., Ph.D., Su Kyung Lee, M.S., Seon Hee Shin, M.D., Ph.D., Jin Soo Kim, M.D., Ph.D., Heungjeong Woo, M.D., Ph.D., Eun-Jung Cho, M.D., Ph.D., Jungwon Hyun, M.D., Ph.D., Jae-Seok Kim, M.D., Ph.D., and Hyun Soo Kim, M.D., Ph.D.. Ann Lab Med 2023;43:434-42. https://doi.org/10.3343/alm.2023.43.5.434

1 March 2021 in Annals of Laboratory Medicine
Verified
Journal Article
Open access
PDF file
SLSu-Kyung Lee
Su-Kyung Lee
SOSu Jin Oh
Su Jin Oh
SCSeoheui Choi
Seoheui Choi
SCSoo-Han Choi
Soo-Han Choi
SSSeon Hee SHIN
Seon Hee SHIN
HKHyun Soo Kim
Hyun Soo Kim
Su-Kyung Lee, M.S., Su Jin Oh, M.S., Seoheui Choi, M.D., Soo Han Choi, M.D., Seon-Hee Shin, M.D., Eun Jin Lee, M.D., Eun-Jung Cho, M.D., Jungwon Hyun, M.D., Hyun Soo Kim, M.D.. Ann Lab Med 2021;41:181-9. https://doi.org/10.3343/alm.2021.41.2.181

13 April 2026 in Vaccines
Verified
Journal Article
Open access
PDF file
YYYoonsun Yoon
Yoonsun Yoon
HCHye-Kyung Cho
Hye-Kyung Cho
KKKi Hwan Kim
Ki Hwan Kim
SPSu Eun Park
Su Eun Park
YKYae-Jean Kim
Yae-Jean Kim
YKYun-Kyung Kim
Yun-Kyung Kim
Background: Influenza causes substantial morbidity in young children, particularly those aged 6–35 months. In this age group, optimisation of vaccine dose regimens remains important to ensure adequate immunogenicity while maintaining acceptable safety. This study evaluated the immunogenicity and safety of a full 0.5 mL dose of quadrivalent inactivated influenza vaccine (NBP607-QIV) in young children. Methods: This Phase 3, randomised, double-blind, active-controlled, multicentre study was conducted in Korea, Thailand, and Malaysia. Healthy children aged 6–35 months were randomised 2:1 to receive NBP607-QIV (0.5 mL) or control vaccine (0.25 mL). Immunogenicity was assessed using the haemagglutination inhibition assay. Primary endpoints were non-inferiority of NBP607-QIV versus Agrippal for seroconversion rate (SCR) and adjusted post-vaccination geometric mean titre (GMT) ratio against three shared strains. Immunogenicity against the additional B/Yamagata strain was evaluated according to Committee for Medicinal Products for Human Use (CHMP) criteria. Safety was assessed based on adverse events. Results: A total of 676 participants were randomised, and 675 were included in the safety set. Non-inferiority of NBP607-QIV versus control vaccine was demonstrated for SCR for all shared strains and for the adjusted GMT ratio for A/H1N1 and B/Victoria, but not for A/H3N2. Immunogenicity against the B/Yamagata strain met CHMP criteria for SCR and geometric mean ratio (GMR). Immunogenicity was consistent across prespecified subgroups, and the incidence of adverse events was comparable between groups, with no clinically meaningful safety concerns. Conclusions: NBP607-QIV administered at a 0.5 mL dose demonstrated acceptable immunogenicity and a safety profile comparable to that of a licensed trivalent influenza vaccine in children aged 6–35 months, supporting its use in this paediatric population.